Bangkok, Thailand

Philippe Louis Leboulch

USPTO Granted Patents = 5 

Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2017-2023

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Philippe Louis Leboulch: Innovator in Gene Therapy

Introduction

Philippe Louis Leboulch is a prominent inventor based in Bangkok, Thailand. He has made significant contributions to the field of gene therapy, particularly in the development of therapeutic retroviral vectors. With a total of five patents to his name, Leboulch's work focuses on improving gene therapy methods for hematopoietic cells and related disorders.

Latest Patents

Leboulch's latest patents include innovative compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells. These advancements encompass erythrocytes, erythroid progenitors, and embryonic stem cells. His inventions provide improved gene therapy methods for treating hematopoietic-related disorders. Additionally, he has developed retroviral gene therapy vectors optimized for erythroid-specific expression and the treatment of hemoglobinopathic conditions.

Career Highlights

Throughout his career, Philippe Louis Leboulch has worked with notable organizations such as Bluebird Bio, Inc. and the Massachusetts Institute of Technology. His experience in these institutions has allowed him to advance his research and contribute to the field of gene therapy significantly.

Collaborations

Some of his notable coworkers include Robert Pawliuk and Karen Westerman. Their collaborative efforts have further enhanced the impact of Leboulch's research in gene therapy.

Conclusion

Philippe Louis Leboulch is a key figure in the field of gene therapy, with a focus on hematopoietic cells and innovative therapeutic methods. His contributions through patents and collaborations continue to shape advancements in this critical area of medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…